Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance (Q38132359)

29 August 2017

title

Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance (English)

1 reference

29 August 2017

1 reference

Steve A Maxwell

1

1 reference

29 August 2017

Seyed Mousavi-Fard

series ordinal

2

1 reference

29 August 2017

publication date

28 August 2013

1 reference

Experimental Biology and Medicine

29 August 2017

published in

1 reference

29 August 2017

volume

238

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

971-990

1 reference

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Monoclonal antibody as therapy for malignant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Germinal centres: role in B-cell physiology and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Prognostic factors in aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Non-Hodgkin's lymphoma: review of conventional treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Therapy of non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Non-Hodgkin lymphoma: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Novel therapies in peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Therapy of mantle cell lymphoma: current standards and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Biology and management of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The complex landscape of genetic alterations in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mantle cell lymphoma: advances in biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

High level of glutathione-S-transferase pi expression in mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

How I treat mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The PI3K/Akt pathway as a target in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mutations of the PIK3CA gene in diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Smad6 inhibits signalling by the TGF-beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

BCL6 represses Smad signaling in transforming growth factor-beta resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Akt regulates the survival of vascular smooth muscle cells via inhibition of FoxO3a and GSK3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The glamour and gloom of glycogen synthase kinase-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Chemical biology investigation of cell death pathways activated by endoplasmic reticulum stress reveals cytoprotective modulators of ASK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

PP2A regulates the pro-apoptotic activity of FOXO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

CD95's deadly mission in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Apoptosis signaling in lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Cell death: critical control points

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

How the Bcl-2 family of proteins interact to regulate apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Apoptosis: a link between cancer genetics and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Bcl-2 and the regulation of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Bcl-2 antisense therapy in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The central effectors of cell death in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A single ataxia telangiectasia gene with a product similar to PI-3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

21 January 2018

Signaling to NF-kappaB

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

NF-kappaB and IKK as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A microRNA polycistron as a potential human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Thymocytes selected for resistance to hydrogen peroxide show altered antioxidant enzyme profiles and resistance to dexamethasone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Overexpression of catalase or Bcl-2 alters glucose and energy metabolism concomitant with dexamethasone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Why do cancers have high aerobic glycolysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Enhancement of chemotherapy by manipulation of tumour pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Tumor acidity, chemoresistance and proton pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Plasmalemmal vacuolar-type H+-ATPase in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Glutathione and related enzymes in multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rituximab therapy in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Caspase-independent killing of Burkitt lymphoma cell lines by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The association between CD20 and Src-family Tyrosine kinases requires an additional factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Regulation of Multidrug Resistance in Cancer Cells by Hyaluronan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Tumorigenic potential of extracellular matrix metalloproteinase inducer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Cell biological mechanisms of multidrug resistance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Biochemistry of multidrug resistance mediated by the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Immunohistochemical detection of the multidrug transport protein P1 70 in human normal tissues and malignant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The drug resistance-related protein LRP is the human major vault protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Prognostic value of GST-pi expression in diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Differential induction of apoptosis and MAP kinase signaling by mitochondrial toxicants in drug-sensitive compared to drug-resistant B-lineage lymphoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

B cell antigen receptor signaling 101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

ITAM-mediated tonic signalling through pre-BCR and BCR complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Glucocorticoid resistance in childhood leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Proteasome inhibitors in cancer therapy: lessons from the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mechanisms of proteasome inhibitor action and resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Lysosomal cysteine proteases: facts and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Stress induction of GRP78/BiP and its role in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The role of histone deacetylases (HDACs) in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Signaling network model of chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Clues to the pathogenesis of familial colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Microsatellite instability in cancer of the proximal colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Chemokine requirements for B cell entry to lymph nodes and Peyer's patches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

p105 and p98 precursor proteins play an active role in NF-kappa B-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Drug-target interactions: only the first step in the commitment to a programmed cell death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Social controls on cell survival and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Double identity for proteins of the Bcl-2 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

DNA damage-mediated induction of a chemoresistant niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Sphingosine kinase, sphingosine-1-phosphate, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The diversity of Rab proteins in vesicle transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Rab proteins as membrane organizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Gallium nitrate in the treatment of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Regulation of plasma-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Regulatory events in early and late B-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mantle cell lymphoma activation enhances bortezomib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Circulating clonotypic B cells in classic Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Characterization of clonogenic multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

A proteolytic system that compensates for loss of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1535370213498985

21 January 2018

Identifiers

DOI

10.1177/1535370213498985

1 reference

release_dt372vmjmbdpriawekyxc5b3se

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dt372vmjmbdpriawekyxc5b3se

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference